IL10 and neoplasm: This has recently been described for pegylated recombinant IL-10, which stimulated the activation, expansion, and cytotoxicity of tumor-infiltrating CD8+ T cells, while increased levels of immune stimulatory cytokines and antitumor activity were observed in patients with solid tumors who received pegylated recombinant IL-10 [31].